Specifically, IL-17 induces the expressions of CXCL1, CXCL5, CXCL6, and CXCL8, enhancing myeloid-derived suppressor cell function in breast cancer, suppressing T-cell infiltration in lymphoma models, recruiting tumor-associated macrophages in pancreatic cancer, and supporting angiogenesis andin vivo tumor growth in lung cancer[45]. Here, CXCL5 is linked to breast cancer.